Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics (RNTX) entered a third Pre-Paid Advance with Yorkville. On October 23, 2025, the company drew a $1.0 million Pre-Paid Advance, receiving net proceeds of $0.95 million. Under the existing agreement, advances are purchased at 95% of face value, accrue interest at 8% annually (rising to 18% upon certain defaults), and mature 12 months after issuance.
The PPA permits Yorkville to require the company to issue common stock to offset outstanding balances. Earlier tranches included a $1.0 million First Advance on July 29, 2025 and a $1.0 million Second Advance on September 8, 2025, each providing $0.95 million in net proceeds. As of this report, the company issued 953,765 shares at an average price of approximately $1.0562 to offset $1,007,342 under the First Advance, and 927,107 shares at an average price of approximately $1.0825 to offset $1,003,573 under the Second Advance. The third advance was completed as a private placement relying on Section 4(a)(2).
Rein Therapeutics, Inc. furnished a current report on Form 8-K noting that the company issued a press release dated October 9, 2025. The filing indicates the press release was provided as an interactive data file within the Inline XBRL document and is signed by Brian Windsor, Ph.D., Chief Executive Officer.
No financial results, transactions, corporate developments, or other substantive disclosures are included in the text provided here; the filing appears limited to furnishing the press release.
Voss-affiliated investors reported initial beneficial ownership in Rein Therapeutics, Inc. (RNTX). The Form 3, covering an event dated 09/24/2025 and filed on 10/03/2025, shows the filing group collectively beneficially owns over 10% of Rein Therapeutics common stock. The filing lists Voss Value Master Fund, LP with 699,440 shares and Voss Value-Oriented Special Situations Fund, LP with 316,768 shares, held indirectly through Voss Advisors GP, LLC, Voss Capital, LP and Travis W. Cocke. The report is a joint Form 3 by multiple Voss entities and Mr. Cocke and disclaims ownership beyond pecuniary interest.
Rein Therapeutics, Inc. receives a Schedule 13G/A disclosing that several Voss-related entities and Travis W. Cocke hold meaningful stakes in the company. The filing reports specific beneficial ownership amounts: Voss Value Master Fund holds 699,440 shares (3.0%), Voss Value-Oriented Special Situations Fund holds 316,768 shares (1.3%), Voss Advisors GP is attributable to 1,016,208 shares (4.3%), and Voss Capital and Travis W. Cocke are each reported as beneficial owners of 2,666,532 shares (11.3%). Those percentages are calculated against 23,547,429 shares outstanding as disclosed in the issuer’s registration statement. The cover pages show sole voting and dispositive power for the reported amounts and the filing includes a certification that the shares were not acquired to change or influence control of the issuer.
Rein Therapeutics (RNTX) reports that the RENEW Phase 2 clinical trial is subject to a clinical hold, creating uncertainty about timing and the studies or actions needed to resolve the hold. The company warns that delays could strain its cash resources and affect its ability to fund the trial and operations through completion. It also notes the risk that early-stage results may not be replicated later, potential difficulties enrolling patients, and challenges integrating Qureight's deep-learning platform into the trial. The filing points readers to the company’s 2024 Form 10-K for additional risk factors and reiterates standard forward-looking statement disclaimers.
Rein Therapeutics, Inc. (RNTX) entered a Pre-Paid Advance Agreement with YA II PN, Ltd. (Yorkville) allowing up to $6.0 million of prepaid advances over 12 months, each purchased at 95% of face value and due 12 months after issuance. Interest on outstanding advances accrues at 8% annually, rising to 18% upon certain defaults. An initial $1.0 million advance was purchased on the effective date for net proceeds of $0.95 million. The company issued 479,036 shares of common stock (average price ~$1.06 per share) to Yorkville, which were applied against $500,000 of the initial advance. The placement was done in a private transaction relying on Section 4(a)(2) of the Securities Act with no underwriter.
Rein Therapeutics, Inc. (RNTX) is registering shares in connection with a standby equity purchase agreement and related prepaid advance facility with Yorkville/YA II PN, Ltd. The company is developing peptide and proenzyme candidates LTI-03 and LTI-01 for fibrosis-related lung diseases; LTI-03 is the lead program with Phase 1b data and a planned 24-week RENEW trial, with initial data expected in 2026. LTI-01 completed Phase 2a and Phase 1b work but its development has been temporarily delayed and may remain paused pending funding. Under the Pre-Paid Advance Agreement, Rein may request up to $6.0 million in prepaid advances (purchased at a 5% discount) and has received an initial $1.0 million advance (net $950,000). Under the Standby Equity Purchase Agreement, the company could receive up to $15.0 million in aggregate gross proceeds if it sells Advance Shares to the selling stockholder; outstanding and potential share counts are disclosed.
Rein Therapeutics, Inc. reported that it issued a press release about the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. The company used this report to formally note the communication to the market and attached the press release as an exhibit for investors to review.
The filing does not provide clinical, financial, or operational details about the Phase 2 trial itself, but directs readers to the full press release, dated August 19, 2025, for more information on the LTI-03 development plans.
On 29 Jul 2025 Rein Therapeutics (RNTX) entered two financing arrangements with YA II PN, Ltd. 1) Pre-Paid Advance Agreement (PPA): the company can draw up to $6.0 m over 12 months; Yorkville purchases each advance at 95% of face value (initial draw $1.0 m yielded $0.95 m). Interest accrues at 8% (18% upon default). Yorkville may force repayment in shares at the lower of 115% of prior-day VWAP or 95% of the lowest VWAP in the prior 7 trading days, but not below a $0.28 floor. Floor-price, registration-effectiveness or exchange-cap breaches trigger monthly cash amortization of up to 25% of the original advance.
2) Standby Equity Purchase Agreement (SEPA): provides an equity line of up to $15.0 m over 36 months. Each advance is priced at 96% of the lowest VWAP during the three days after an advance notice, subject to volume and minimum-price limits. Rein paid a $300 k commitment fee via 213,099 shares and $25 k expenses.
The aggregate shares issuable under both facilities are capped at 19.9% of current outstanding stock, and Yorkville’s ownership is limited to 4.99%. PPA shares will be issued off the company’s shelf registration; SEPA shares require an effective resale registration statement. The facilities give Rein up to ~$21 m in gross liquidity with flexible timing, but at the cost of discounted pricing, possible dilution and potential downward pressure on the share price.